KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Moderna (MRNA) EBIAT (2017 - 2025)

Moderna (MRNA) has disclosed EBIAT for 9 consecutive years, with -$826.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT rose 26.25% to -$826.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 billion, a 20.75% increase, with the full-year FY2025 number at -$2.8 billion, up 20.75% from a year prior.
  • EBIAT was -$826.0 million for Q4 2025 at Moderna, down from -$200.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $4.9 billion in Q4 2021 to a low of -$3.6 billion in Q3 2023.
  • A 5-year average of $473.4 million and a median of $46.0 million in 2023 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: surged 2481.91% in 2021, then tumbled 1638.46% in 2025.
  • Moderna's EBIAT stood at $4.9 billion in 2021, then plummeted by 69.91% to $1.5 billion in 2022, then crashed by 85.19% to $217.0 million in 2023, then crashed by 616.13% to -$1.1 billion in 2024, then increased by 26.25% to -$826.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's EBIAT are -$826.0 million (Q4 2025), -$200.0 million (Q3 2025), and -$825.0 million (Q2 2025).